NANJING, China, July 23, 2024–(BUSINESS WIRE)–Triastek Inc. (“Triastek”), a global leader in 3D printing pharmaceuticals, today announced that it has entered into a research collaboration and platform technology license agreement with BioNTech SE (“BioNTech”), a next-generation immunotherapy company pioneering new treatments for cancer and other serious diseases. Under the agreement, the two companies will develop orally administered RNA therapeutics based on 3D printing technology. The collaboration aims to deliver breakthrough therapies addressing unmet medical needs in an easy-to-administer oral formulation.
Triastek will contribute its expertise in innovative oral tablet designs enabled by 3D printing to this collaboration. The designs aim to optimize delivery of RNA therapeutics across the GI mucosa, minimize digestive degradation, and deliver RNA therapeutics to parts of the GI tract where absorption is likely to be highest. Leveraging Triastek’s capabilities in creating tablet structures with unique external and internal tablet geometries, including multi-layered and multi-compartment designs, the collaboration aims to optimize the delivery of novel RNA therapeutics.
“We are honored to announce our collaboration with BioNTech, a leader in revolutionizing patient care with innovative medicines,” said Dr. Senping Cheng, founder and CEO of Triastek. “This collaboration marks a promising milestone in the advancement of oral RNA therapeutics using 3D printing technology and aims to set a new benchmark in the development of large molecule oral drugs. We are committed to working together diligently to realize breakthroughs in the oral delivery of RNA therapeutics.”
Under the terms of the agreement, Triastek will receive an upfront payment of $10 million and will be eligible to receive development, regulatory and commercial milestone payments totaling more than $1.2 billion, as well as tiered royalties on potential future product sales.
About Triastec
Founded in July 2015, Triastek is dedicated to its mission of “revolutionizing the pharmaceutical industry, pioneering the next generation of medicines and benefiting patients worldwide.” The company pioneered the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process to transform drug delivery, development and production through digital product development and continuous manufacturing.
Leveraging our proprietary 3D printing pharmaceutical technology, we design and develop innovative medicines for patients. Through collaborations with global pharmaceutical companies, we address challenging formulation problems, accelerate drug development, and improve drug quality.
The story continues
Our vision is to become the world’s most influential intelligent pharmaceutical company.
Triastek’s systematic technology and applications
Triastek develops Melt Extrudeposition (MED®) 3D printed pharmaceutical technology, develops and builds new 3D printed pharmaceutical technology systems encompassing new processes/equipment, new platforms and new products, and provides end-to-end technology solutions for pharmaceuticals including design, development, manufacturing and commercial supply.
Leveraging MED® technology, Triastek has built three pharmaceutical processes: MED® process, Melt Extrusion Deposition plus Micro Injection Molding (MED&MIM) process, and Melt Extrusion Deposition plus Semi-Solid Extrusion (MED&SSE) process. Triastek has also developed five 3D microstructured drug delivery technology platforms, including controlled release, solubility enhancement, colon targeting, gastric retention, and oral peptide, and has developed a pipeline of multiple 3D printed drug products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723000417/en/
contact address
public relations
Lily Chen
chenshuaiton@triastek.com
